Jennifer A. Woyach, MD
With therapeutic additions to the treatment paradigm of chronic lymphocytic leukemia (CLL), it is now a question of which regimen to give patients in the frontline setting, explained Jennifer A. Woyach, MD.
“In the frontline setting, our new options for targeted therapy include ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta) plus obinutuzumab (Gazyva). We have 3 great targeted therapy options. One of the difficulties right now is that we have such great options. [Which patient] do we choose for which agent?” said Woyach.
Acalabrutinib was the most recent BTK inhibitor to be approved in the CLL pipeline. The agent was approved based on data from the phase III ELEVATE-TN trial, which examined acalabrutinib alone versus acalabrutinib/obinutuzumab versus obinutuzumab/chlorambucil in treatment-naïve patients with CLL. At a median follow-up of 28.3 months, the combination of acalabrutinib plus obinutuzumab
resulted in a 90% reduction in the risk of disease progression or death versus obinutuzumab/chlorambucil (HR, 0.10; 95% CI, 0.06-0.17; P
Acalabrutinib monotherapy also showed a significant benefit in progression-free survival (PFS; HR, 0.20; 95% CI, 0.13-0.30; P
... to read the full story